TGTyler E. Gaston

Tyler E. Gaston

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tyler E. Gaston has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validation of drug‐resistant epilepsy identification algorithms in US Veterans across diverse care settings

    by Zulfi Haneef, Rohan S. Nagabhirava, Andrea D. Hildebrand, Richard Zhou, Sruthi Gopinath Karicheri, Stephan Eisenschenk, Marcella A. Coutts, Maria Raquel Lopez, Omar I. Khan, Rizwana Rehman, et al.

    Objective: Early recognition of drug‐resistant epilepsy (DRE) is critical for timely referral to comprehensive epilepsy centers (CECs). Our prior pilot study in the Veterans Health Administration (VHA) demonstrated the feasibility of an algorithm‐based approach to identify DRE within selected CECs. In this study, we validated and refined these algorithms in a broader, national cohort, including CEC and non‐CEC care, to optimize algorithms for different care settings. Methods: We conducted a multicenter, retrospective study of randomly sampled veterans with epilepsy on ≥2 antiseizure medications (ASMs) from 1999 to 2024. Chart review by 26 epilepsy providers rated DRE status. Ninety‐six candidate algorithms using combinations of six criteria—number of ASMs, treatment duration, dose thresholds, pregabalin exclusion, intractable International Classification of Diseases (ICD) codes, and electroencephalography (EEG)/magnetic resonance imaging (MRI) utilization—were evaluated. Performance for DRE classification was evaluated among all veterans, and separately for CEC or non‐CEC care. Results: Among 970 veterans on ≥2 lifetime ASMs, 518 (53.4%) were rated as DRE, 363 (37.4%) as non‐DRE, and 89 (9.2%) as undetermined. Veterans with DRE were younger (mean age = 68.9 vs. 72.0 years) and more frequently had at least one intractable ICD code (46.1% vs. 18.2%), EEG (77.8% vs. 66.7%), or MRI (78.0% vs. 65.8%) compared with non‐DRE (all p ‐values <.001). Among all veterans, the best overall algorithm (area under the curve [AUC] = .701) identified DRE as either (1) exposure to 3+ ASMs or (2) exposure to two ASMs for at least 1 year, with the requirement of past EEG/MRI and intractable ICD code documentation. This algorithm was also highly effective among veterans who received CEC (AUC = .756) or only non‐CEC care (AUC = .678). Significance: This national validation study confirms that medication‐based algorithms can identify DRE within VHA administrative data across care settings (CECs and non‐CECs). This supports the implementation of a standardized DRE definition for quality improvement, surveillance, and referral optimization within the VHA.

  • Late-Onset Seizures

    by Leah J. Blank, Emily L. Johnson, Kyle R. Pellerin, Rani A. Sarkis, Tyler E. Gaston, Mouhsin M. Shafi, Rodrigo Zepeda, Maria Camitan, Tania Anderson, Alexis Hankerson, et al.

    Adults older than age 55 years have the highest incidence rate and are the fastest-growing population among people with epilepsy. The aim of this study was to characterize the etiologies of new-onset seizures in older adults and to examine how seizure etiology varies across demographic groups. We used data from 7 US epilepsy centers from 2021 to 2025 and compared findings with those of previous population-based studies, providing an updated view and highlighting opportunities for prevention and improved risk stratification. We retrospectively reviewed medical charts of 2,052 patients aged ≥55 years at the time of a first seizure, who were evaluated at 7 epilepsy centers between 2021 and 2025. We categorized seizures by etiology as follows: ischemic stroke, hemorrhagic stroke, tumor, neurodegeneration, provoked seizures, traumatic brain injury, and unknown. We examined differences in etiology by demographic strata (age, sex, race, and primary language) using chi-square tests, Kruskal-Wallis tests, analysis of variance, and Cuzick tests. The most frequent seizure etiologies among older adults were unknown (29.9%), ischemic stroke (15.4%), and provoked seizures (14.9%). Neurodegenerative disease was the etiology for 5.3% of cases overall but increased in prevalence with age, accounting for 18.5% among patients aged 85-89 years. Seizure etiologies also differed by sex and race. Men more commonly had seizures caused by cerebrovascular disease and traumatic brain injury, while women more commonly had seizures due to neurodegenerative disease. Black patients had higher proportions of ischemic stroke and neurodegenerative disease, while unexplained epilepsy was more common among White patients. The causes of late-onset seizures vary based on age, sex, and race. Nearly one-third of cases of epilepsy in older adults remain unexplained despite advances in imaging techniques, underscoring the need for further research on the mechanisms and health implications of late-onset unexplained epilepsy. Improved prevention of cerebrovascular disease and optimized management of provoked seizures may reduce the growing burden of epilepsy in older adults.


  • Open Access

    Late‐onset unexplained epilepsy as a risk factor for cognitive impairment and dementia: Protocol for a multi‐center prospective longitudinal observational study ( ELUCID )

    by Alice D. Lam, Emily L. Johnson, Rani A. Sarkis, Leah J. Blank, Tyler E. Gaston, Mouhsin M. Shafi, Rodrigo Zepeda, Kyle R. Pellerin, Nathalie Jette, Douglas N. Greve, et al.

    Objective: Late‐onset unexplained epilepsy (LoUE), defined as epilepsy onset after age 55 without an obvious cause, is an important risk factor for dementia. Studies have shown that 10%–25% of individuals with LoUE develop dementia within 3–4 years following their first seizure. However, the mechanisms underlying progression from LoUE to dementia remain poorly understood. The goals of the ELUCID study are to identify risk factors associated with the development of cognitive decline and dementia in LoUE and to develop tools to identify patients at a high risk for these outcomes and thereby establish a foundation for dementia prevention strategies in this population. Methods and Analysis: ELUCID is a multi‐center prospective longitudinal observational study that will enroll 600 participants aged 55 or older with LoUE across seven U.S. medical centers. Participants will undergo a baseline evaluation that includes a detailed clinical history, cognitive testing, brain MRI, overnight scalp EEG, and blood biomarkers. Participants will be followed at 6‐month intervals for up to 5 years, to record cognitive and neurological changes, with the primary outcomes of interest being the development of mild cognitive impairment and/or dementia. This study aims to establish LoUE disease subtypes based on biomarkers, cognitive trajectories, and imaging features and to develop a risk stratification tool for predicting cognitive decline and dementia in patients presenting with LoUE. Ethics and Dissemination: ELUCID has obtained IRB approval (no. 2023P001566, August 2023), with the Mass General Brigham IRB serving as the single IRB of record. All de‐identified study data will be made publicly available on completion of the study. Plain Language Summary: The ELUCID study is a research project involving several medical centers across the U.S. It will focus on older adults who have recently developed seizures without a clear cause. Participants undergo an initial evaluation that includes questions about their medical history, a brain MRI , an overnight scalp EEG (brain wave study), and a blood draw. They will be followed over time with health questionnaires and yearly tests of memory and thinking. The purpose of the study is to learn what factors increase the risk of dementia in this population and to develop tools to predict which individuals are at the highest risk.


  • Open Access

    Neurobehavioral therapy in functional seizures: Investigation of mechanism of action with resting‐state functional magnetic resonance imaging

    by Jerzy P. Szaflarski, W. Curt LaFrance, Rodolphe Nenert, Jane B. Allendorfer, Stephen Correia, Tyler E. Gaston, Adam M. Goodman, Leslie E. Grayson, Noah Philip

    Objective: Functional seizures (FS) often disrupt the key regions integral to cognitive processing and emotional regulation (anterior insula, anterior cingulate, and temporoparietal junction). We investigated the potential neurophysiologic mechanism of action (MOA) of neurobehavioral therapy (NBT) using resting‐state functional MRI seed‐based whole‐brain functional connectivity within these regions in adults with FS. We hypothesized that NBT would induce changes in functional connectivity in parallel with improving seizure frequency and behavioral outcomes.Methods: Forty patients with traumatic brain injury and FS (TBI+FS) underwent 12 weekly sessions of NBT and provided pre‐/post‐intervention resting‐state functional magnetic resonance imaging (MRI), seizure logs, and behavioral assessments. Fifty‐five individuals with TBI without FS (TBI‐only) completed the same measures, received standard medical care but not NBT, and functional MRI ~12 weeks apart. For each key region, two‐sample t‐tests assessed direct group comparison. Repeated measures analysis of covariance assessed how group differences evolved over time and how these changes were modulated by the changes in seizure frequency, diagnosis duration, or behavioral scores (false discovery rate corrected at p < .05).Results: With NBT, seed‐based whole‐brain functional connectivity was significantly higher between right anterior insula and left supplementary motor area in TBI+FS compared to TBI‐only, and between left anterior insula and left postcentral gyrus in seizure‐free TBI+FS compared to those who were not seizure‐free. Percentage decrease in seizure frequency with NBT was associated with lower functional connectivity between bilateral insula and left superior medial frontal gyrus in patients with FS. Improvements in behavioral measures did not correspond to changes in functional connectivity.Significance: The study underscores the relationship between the changes in resting‐state functional connectivity of the anterior insula in FS and treatment response to NBT and illustrates the potential neurophysiologic MOA of NBT for the treatment of FS; it suggests an independence of this MOA from the potential effects of NBT on behavioral measures.


  • One‐year follow‐up of neurobehavioral therapy in functional seizures or epilepsy with traumatic brain injury: A nonrandomized controlled trial

    by Ryan Van Patten, Andrew Blum, Stephen Correia, Noah S. Philip, Jane B. Allendorfer, Tyler E. Gaston, Adam Goodman, Leslie P. Grayson, Krista Tocco, Valerie Vogel, et al.

    Objective: Patients with traumatic brain injury (TBI) often present with seizures (functional and/or epileptic), but treatments for patients with TBI and seizures are limited. We examined treatment phase and 1‐year post‐enrollment outcomes following neurobehavioral therapy (NBT) for patients with TBI + functional seizures (FS) and TBI + epilepsy.Methods: In this multicenter, prospective, three‐group, nonrandomized, controlled trial, with 1‐year post‐enrollment follow‐up, three cohorts of adults were recruited: TBI + video‐electroencephalography (EEG)‐confirmed FS (n = 89), TBI + EEG‐confirmed epilepsy (n = 29), and chart/history‐confirmed TBI without seizures (n = 75). Exclusion criteria were recent psychotic or self‐injurious behavior, current suicidal ideation, pending litigation or long‐term disability, active substance use disorder, and inability to participate in study procedures. TBI + FS and TBI + epilepsy groups completed NBT for seizures, an evidence‐based, 12‐session, multimodal psychotherapy, whereas TBI without seizures participants received standard medical care. The primary outcome was change in seizure frequency; secondary outcomes were changes in mental health, TBI‐related symptoms, disability, and quality of life.Results: Reductions in average monthly seizures occurred during treatment in TBI + FS participants (p = .002) and were significant from baseline (mean = 16.75; 95% confidence interval [CI] = 11.44–24.53) to 12 months post‐enrollment (mean = 7.28, 95% CI = 4.37–12.13, p = .002, d = .38). Monthly seizures decreased during treatment in TBI + epilepsy participants (p = .002); reductions were not statistically significant from baseline (mean = 2.38, 95% CI = 1.12–5.04) to 12‐month postenrollment (mean = .98, 95% CI = .40–2.42, p = .07, d = .22). Regarding treatment‐phase changes in secondary outcome measures, TBI + FS participants improved significantly on 10 of 19 variables (52.6%), TBI + epilepsy participants improved on five of 19 (26.3%), and TBI‐only comparisons improved on only one of 19 (5.3%).Significance: NBT benefited patients with TBI + FS and TBI + epilepsy. Improvements were demonstrated at 1 year post‐enrollment in those with TBI + FS. NBT may be a clinically useful treatment for patients with seizures.


  • Open Access

    Final analysis of potential drug–drug interactions between highly purified cannabidiol and anti‐seizure medications in an open‐label expanded access program

    by Tyler E. Gaston, E. Martina Bebin, Gary R. Cutter, Leslie Grayson, Jerzy P. Szaflarski

    Objective: The aim of this study was to assess potential drug–drug interactions between highly purified cannabidiol (CBD) and anti‐seizure medications (ASMs).Methods: Our group previously reported that in a sample of adults and children receiving CBD in an open‐label expanded access program, there were several ASMs noted to increase in serum levels with increasing doses of CBD. We analyzed if an increased number of observations over time resulted in changes in potential interactions and if potential interactions were associated with time since enrollment, demographics, or the overall rating of adverse effects.Results: In 169 participants (80 adults), with increasing weight‐based CBD dose, there were associated increases in serum levels of clobazam and N‐desmethylclobazam, free valproate, felbamate, and topiramate in the adult and pediatric arms combined, levetiracetam in the pediatric arm only, and permapanel in the adult arm only. There were no associations noted in these level changes with time since enrollment, biological sex, and adverse events profile scores.Significance: This study confirms some previously identified interactions with CBD and identifies other potential pharmacokinetic interactions; however, the clinical significance of these observations is likely minor, and there is no effect of time on these findings.


  • Cannabidiol (CBD) and cognition in epilepsy

    by Tyler E. Gaston, Roy C. Martin, Jerzy P. Szaflarski


  • Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy

    by Tyler E. Gaston, Steve B. Ampah, E. Martina Bebin, Leslie P. Grayson, Gary R. Cutter, Kathleen Hernando, Jerzy P. Szaflarski


  • Effects of highly purified cannabidiol (CBD) on fMRI of working memory in treatment-resistant epilepsy

    by Tyler E. Gaston, Jane B. Allendorfer, Sangeeta Nair, E. Martina Bebin, Leslie P. Grayson, Roy C. Martin, Jerzy P. Szaflarski


  • Open Access

    White matter and neurite morphology differ in psychogenic nonepileptic seizures

    by Adam M. Goodman, Jane B. Allendorfer, Andrew S. Blum, Mark S. Bolding, Stephen Correia, Lawrence W. Ver Hoef, Tyler E. Gaston, Leslie E. Grayson, Nina V. Kraguljac, Adrienne C. Lahti, et al.

    Objective: To further evaluate the relationship between the clinical profiles and limbic and motor brain regions and their connecting pathways in psychogenic nonepileptic seizures (PNES). Neurite Orientation Dispersion and Density Indices (NODDI) multicompartment modeling was used to test the relationships between tissue alterations in patients with traumatic brain injury (TBI) and multiple psychiatric symptoms.Methods: The sample included participants with prior TBI (TBI; N = 37) but no PNES, and with TBI and PNES (TBI + PNES; N = 34). Participants completed 3T Siemens Prisma MRI high angular resolution imaging diffusion protocol. Statistical maps, including fractional anisotropy (FA), mean diffusivity (MD), neurite dispersion [orientation dispersion index (ODI)] and density [intracellular volume fraction (ICVF), and free water (i.e., isotropic) volume fraction (V‐ISO)] signal intensity, were generated for each participant. Linear mixed‐effects models identified clusters of between‐group differences in indices of white matter changes. Pearson’s r correlation tests assessed any relationship between signal intensity and psychiatric symptoms.Results: Compared to TBI, TBI + PNES revealed decreases in FA, ICVF, and V‐ISO and increases in MD for clusters within cingulum bundle, uncinate fasciculus, fornix/stria terminalis, and corticospinal tract pathways (cluster threshold α = 0.05). Indices of white matter changes for these clusters correlated with depressive, anxiety, PTSD, psychoticism, and somatization symptom severity (FDR threshold α = 0.05). A follow‐up within‐group analysis revealed that these correlations failed to reach the criteria for significance in the TBI + PNES group alone.Interpretation: The results expand support for the hypothesis that alterations in pathways comprising the specific PNES network correspond to patient profiles. These findings implicate myelin‐specific changes as possible contributors to PNES, thus introducing novel potential treatment targets.